TRIM28 is a target for paramyxovirus V proteins
Related Experiment Video
Updated: Jan 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Gauthier Lieber1, Florence Kwaschik1, Marie Lork1
1Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
Abstract:
SUMO-modified Tripartite Motif Protein 28 (TRIM28; KAP1) plays a crucial role in repressing endogenous retroelement (ERE) transcription. We previously provided evidence that loss of SUMO-modified TRIM28 triggered by influenza A virus (IAV) infection promotes activation of host antiviral immunity via a mechanism involving derepression of EREs and production of immunostimulatory RNAs. While the IAV NS1 protein might limit consequences of such activation via its dsRNA-binding activity, we hypothesized that other human pathogenic viruses could have evolved more direct strategies to counteract this potential ERE-based defense system. Here, we reveal that V proteins from diverse paramyxoviruses, including Measles, Mumps, Parainfluenza, and Nipah/Hendra viruses, can all engage with TRIM28. Notably, the efficiency of engagement varies markedly between virus species, a phenotype that can be linked to specific residues within the C-terminal domain of V proteins. Further mapping showed that V proteins target both the TRIM28 Coiled-Coil domain and the TRIM28 PHD-Bromodomain, which contains the functionally-relevant TRIM28 SUMO-modification sites necessary for ERE repression. In this context, while paramyxovirus infection triggers canonical stress-associated phosphorylation of TRIM28, loss of SUMO-modified TRIM28 does not occur, and minimal induction of the TRIM28-dependent ERE RNA, HERVK14C, is observed. Furthermore, pre-infection with Parainfluenza virus type 2, which encodes a V protein that efficiently engages with TRIM28, limits subsequent IAV-triggered loss of SUMO-modified TRIM28 and upregulation of HERVK14C RNA. These findings dissect the interplay between paramyxoviruses and TRIM28, providing support for the concept of a TRIM28-regulated ERE-based antiviral defense system by uncovering a potential viral antagonistic measure.
Insights
Paramyxoviruses counteract TRIM28-mediated antiviral defense by engaging with TRIM28, preventing retroelement activation. This interaction inhibits host immunity, unlike influenza A virus, revealing a viral strategy against endogenous retroelement repression.
Area of Science:
- Virology
- Molecular Biology
- Immunology
Background:
- SUMO-modified TRIM28 (KAP1) represses endogenous retroelement (ERE) transcription, crucial for host antiviral immunity.
- Influenza A virus (IAV) infection can disrupt TRIM28 SUMOylation, activating immunity via ERE derepression.
- Other viruses may possess distinct mechanisms to evade this TRIM28-dependent defense.
Purpose of the Study:
- To investigate if paramyxoviruses engage with TRIM28 to counteract ERE-based antiviral immunity.
- To identify the molecular basis for TRIM28 engagement by paramyxovirus V proteins.
- To determine the functional consequences of paramyxovirus V protein interaction with TRIM28.
Main Methods:
- Co-immunoprecipitation assays to assess TRIM28-V protein interactions.
- Site-directed mutagenesis to map critical residues in V proteins and TRIM28 domains.
- Quantitative PCR to measure HERVK14C RNA induction.
- Viral infection experiments to evaluate TRIM28 SUMOylation status and immune response.
Main Results:
- V proteins from diverse paramyxoviruses (Measles, Mumps, Parainfluenza, Nipah/Hendra) bind to TRIM28, with varying efficiencies.
- Specific C-terminal residues of V proteins and TRIM28 domains (Coiled-Coil, PHD-Bromodomain) mediate this interaction.
- Paramyxovirus infection prevents loss of SUMO-modified TRIM28 and HERVK14C induction, unlike IAV.
- Pre-infection with Parainfluenza virus type 2 limits IAV-induced TRIM28 modification loss and HERVK14C upregulation.
Conclusions:
- Paramyxoviruses employ V proteins to antagonize the TRIM28-regulated ERE-based antiviral defense system.
- This interaction preserves TRIM28 SUMOylation, inhibiting ERE derepression and immunostimulatory RNA production.
- These findings highlight a novel viral immune evasion strategy and support the role of TRIM28 in innate immunity.

